01—Abstract
Summary
Summary of the 8-K filed September 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc (MDT) has filed an 8-K report detailing a significant debt offering and the redemption of existing notes.
On September 29, 2025, an indirect wholly owned subsidiary, Medtronic, Inc., successfully issued €1.5 billion in aggregate principal amount of senior notes, split between 2.950%a Senior Notes due 2030 and 4.200% Senior Notes due 2045. These new notes are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The primary purpose of this offering is to refinance existing debt.
Medtronic, Inc. expects to use the net proceeds of approximately €1.49 billion to repay Medtronic Luxco's 0.000%b Senior Notes due 2025 and its 2.625% Senior Notes due 2025. Concurrently, Medtronic Luxco has redeemed all outstanding €500 million of its 2.625% Senior Notes due 2025, with this redemption being contingent on the successful completion of the new notes issuance. This strategic debt management indicates Medtronic's effort to optimize its capital structure and extend its debt maturity profile.
02—Key points
Key Highlights
- Issuance of €1.5 billion in new senior notes: €750 million of 2.950% Senior Notes due 2030 and €750 million of 4.200% Senior Notes due 2045.
- Net proceeds from the offering are approximately €1.49 billion, intended for debt repayment.
- Repayment of €500 million in Medtronic Luxco's 2.625% Senior Notes due 2025, with the redemption being conditional on the new notes issuance.
- New notes are guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc.
- The notes are unsecured senior obligations of Medtronic, Inc. and rank equally with existing unsecured senior indebtedness.
- The new notes have been approved for listing on the New York Stock Exchange, indicating market accessibility.
- The offering aims to refinance maturing debt and potentially optimize the company's interest expense and debt maturity profile.
03—Questions
Frequently Asked Questions
What is the main purpose of this debt issuance?
The main purpose of this debt issuance is to refinance maturing debt. Medtronic plans to use the proceeds to repay Medtronic Luxco's 0.000% Senior Notes due 2025 and its 2.625% Senior Notes due 2025. This also coincides with the redemption of Medtronic Luxco's €500 million 2.625% Senior Notes due 2025.
What are the interest rates and maturity dates of the new notes?
Medtronic issued €750 million of 2.950% Senior Notes due October 15, 2030, and €750 million of 4.200% Senior Notes due October 15, 2045.
What is the total amount raised and how will it be used?
Medtronic expects to receive approximately €1.49 billion in net proceeds from the offering. These funds are earmarked for repaying specific maturing senior notes from Medtronic Luxco.
What is the credit standing of these new notes?
The new notes are general unsecured senior obligations of Medtronic, Inc. They rank equally in right of payment with Medtronic, Inc.'s other existing and future unsecured senior indebtedness. The guarantees from Medtronic plc and Medtronic Luxco also rank equally with their respective unsecured senior indebtedness.
04—Continue